Our Review
Acid Test covers the complete history of psychedelic medicine from the 1950s through to the modern MAPS clinical trials, anchored around three real people whose stories intersect in powerful ways. Shroder's approach is narrative journalism at its best — he lets the science and personal experiences speak for themselves without preaching. The book is especially strong on the MDMA-assisted therapy trials for PTSD and the decades-long regulatory battle that Rick Doblin has fought to make psychedelic-assisted therapy a reality.
What makes this book stand out is its balance and accessibility. Unlike many psychedelic books written by advocates, Shroder is a mainstream journalist who approaches the subject with curiosity rather than conviction. The endorsement from Stanislav Grof — who called it "a breath of fresh air after half a century of general hysteria" — speaks to its credibility within the field. Kirkus Reviews praised its clear-eyed account and perceptive criticism of the war on drugs. The main limitation is that it predates the most recent clinical trial results (2014 publication), so readers should supplement with more current sources.
For microdosing practitioners, Acid Test provides essential context for understanding why psychedelic substances were banned, how clinical research is proving their therapeutic value, and what the future of psychedelic-assisted therapy looks like. Understanding this bigger picture helps microdosers articulate why evidence-based approaches to psychedelic use matter, and frames microdosing within the broader movement toward psychedelic medicine.
Key Takeaways
- ✓ Rick Doblin spent 30+ years building MAPS into the organization that got MDMA-assisted therapy into FDA clinical trials — persistence and strategic thinking can overcome seemingly impossible regulatory barriers
- ✓ MDMA-assisted psychotherapy showed response rates of 83% for PTSD in early clinical trials, far exceeding conventional treatments — the evidence for psychedelic-assisted therapy is strong and growing
- ✓ The prohibition of psychedelics was driven more by cultural panic than by scientific evidence of harm — understanding this history is essential for anyone navigating the current legal landscape
- ✓ Set and setting are not just countercultural slogans — they are clinical variables that determine therapeutic outcomes in every major psychedelic trial
- ✓ The distinction between recreational use and therapeutic use matters enormously for both policy and personal practice — and good journalism can bridge this gap for a general audience
Who Should Read This
Anyone who wants to understand the story behind the psychedelic renaissance — particularly how MDMA and LSD went from promising medicines to banned substances and back again. Ideal for readers who enjoyed Michael Pollan's How to Change Your Mind and want a deeper dive into the clinical research and policy battles that made the current wave of psychedelic science possible.
Available Editions
Related Content
Related Substances
Related Terms
Important Legal Notice
⚠️ Personal Responsibility
You use this application entirely at your own risk and responsibility. MicrodosingDiary is only a tool for recording personal experiences.
🚫 Not a Medical Service
This application IS NOT a medical tool, does not provide medical advice, does not diagnose or treat any conditions. Always consult a qualified physician.
⚖️ Legislation and Laws
Many substances used for microdosing are illegal in many countries. Users are fully responsible for complying with local laws. The application does not support or promote illegal activity.
❌ No Guarantees
We provide no guarantees regarding results, safety or efficacy of microdosing. All information is for informational purposes only.
🔞 Age Restriction
Application is intended only for persons over 18 years of age. By using the application you confirm that you are an adult.
🔒 Data Privacy
Your data is private and encrypted. We never share it with third parties without your consent. Application is for personal use only.
By using this application you accept all the above risks and waive any claims against the application operator.